NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for indian men with tough prostate cancer: darolutamide trial launches
Disease control Recruiting nowThis study tests a drug called darolutamide, added to standard hormone therapy, for Indian men with a type of prostate cancer that hasn't spread but is growing despite low testosterone. The main goal is to check safety and side effects in this group. About 50 men will take darolu…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 02:33 UTC
-
New study tracks safety of prostate cancer drug darolutamide in korean patients
Disease control Recruiting nowThis study is checking the safety of a drug called darolutamide in Korean men with a type of prostate cancer that hasn't spread or has spread but responds to hormone therapy. The drug works by blocking male hormones that help cancer grow. Researchers will track side effects and s…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
5,000 men with advanced prostate cancer to be tracked in major new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow 5,000 men with prostate cancer that has come back or spread. The goal is to see what treatments doctors actually use and how the disease progresses over time. Participants are grouped by their cancer stage, from early PSA recurrence to ad…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC